Literature DB >> 8520875

Totally implanted catheters to reduce catheter-related infections in patients receiving interleukin-2: a 2-year experience.

B Escudier1, J L Lethiec, E Angevin, A Andremont, M F Cosset-Delaigue, S Antoun, B Leclercq, G Nitenberg.   

Abstract

A high incidence of bacterial infections has been previously reported during interleukin-2 (IL-2) treatment, mainly due to catheter-related infections. Antibiotic prophylaxis has been successfully used to decrease such infections. The goal of this study was to evaluate an alternative way to reduce catheter-related infections in IL-2-treated patients by the use of totally implanted catheters. A total of 74 patients with metastatic renal cell carcinoma, referred to our institution to receive IL-2 from March 1989 to July 1991, were included in this prospective study. IL-2 was given on a 2-days-a-week schedule (24 x 10(6) IU m-2 day-1) either alone (41 patients) or in association with interferon gamma (33 patients). All these patients were prospectively evaluated for fever, bacteremia and line-site infection. Seven patients (9.5%) had one (2 patients) or more (5 patients) positive blood cultures with Staphylococcus aureus. Antibiotics were used only in 5 patients, and the catheter had to be removed in only 2 of these patients. In the other patients, no further infection developed despite the lack of antibiotics. Moreover, 9 patients had positive blood cultures with Staphylococcus epidermidis (1.9% of total number of blood cultures). In conclusion, a totally implanted catheter appears to reduce the incidence of infections in IL-2-treated patients, at least on a 2-days-a-week schedule.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8520875     DOI: 10.1007/bf00335305

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  18 in total

1.  Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.

Authors:  T Hercend; F Farace; D Baume; F Charpentier; J P Droz; F Triebel; B Escudier
Journal:  J Biol Response Mod       Date:  1990-12

2.  Coagulase-negative staphylococcal bacteremia. Mortality and hospital stay.

Authors:  M A Martin; M A Pfaller; R P Wenzel
Journal:  Ann Intern Med       Date:  1989-01-01       Impact factor: 25.391

3.  Use of prophylactic antibiotics for prevention of intravascular catheter-related infections in interleukin-2-treated patients.

Authors:  L C Hartmann; W J Urba; R G Steis; J W Smith; L A Vander Molen; S P Creekmore; M Sznol; M A Casciano; N Engler; D L Longo
Journal:  J Natl Cancer Inst       Date:  1989-08-02       Impact factor: 13.506

4.  A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy.

Authors:  S N Bock; R E Lee; B Fisher; J T Rubin; D J Schwartzentruber; J P Wei; D P Callender; J C Yang; M T Lotze; P A Pizzo
Journal:  J Clin Oncol       Date:  1990-01       Impact factor: 44.544

5.  Association of interleukin-2 therapy with staphylococcal bacteremia.

Authors:  J M Richards; T A Gilewski; N J Vogelzang
Journal:  Cancer       Date:  1991-03-15       Impact factor: 6.860

6.  Lack of protection against bacterial infections in patients with advanced cancer treated by biologic response modifiers.

Authors:  S Maoleekoonpairoj; A Mittelman; S Savona; T Ahmed; C Puccio; E Gafney; A Skelos; P Arnold; N Coombe; P Baskind
Journal:  J Clin Microbiol       Date:  1989-10       Impact factor: 5.948

7.  IL-2-based immunotherapy alters circulating neutrophil Fc receptor expression and chemotaxis.

Authors:  D Jablons; E Bolton; S Mertins; M Rubin; P Pizzo; S A Rosenberg; M T Lotze
Journal:  J Immunol       Date:  1990-05-01       Impact factor: 5.422

8.  Short-course therapy of catheter-related Staphylococcus aureus bacteremia: a meta-analysis.

Authors:  J A Jernigan; B M Farr
Journal:  Ann Intern Med       Date:  1993-08-15       Impact factor: 25.391

9.  Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinoma.

Authors:  B Escudier; F Farace; E Angevin; F Triebel; S Antoun; B Leclercq; M Brandely; A Aboudaram; G Nitenberg; T Hercend
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

10.  Early evaluation of coagulase negative staphylococcus in blood samples of intensive care unit patients. A clinically uncertain judgement.

Authors:  E Dominguez-de Villota; A Algora-Weber; I Millán; J J Rubio; P Galdos; J M Mosquera
Journal:  Intensive Care Med       Date:  1987       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.